open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2017-10-15
Get Citation

Gaucher disease – recommendations concerning diagnosis, treatment and monitoring

Piotr Hasiński1, Mirosław Bik-Multanowski2, Magdalena Koba-Wszędobył3, Mieczysław Walczak4, Marek Bubnowski5, Agnieszka Milewska-Kranc6, Andrzej Smyk7, Maciej Machaczka89
DOI: 10.1016/j.achaem.2017.10.001
·
Acta Haematol Pol 2017;48(4):222-261.
Affiliations
  1. Oddział Internistyczny o profilu gastroenterologicznym Szpitala Miejskiego w Tychach Sp. z o.o., Kierownik jednostki: lek. Daniela Rubisz-Warmuz, Tychy, Polska
  2. Zakład Genetyki Medycznej Collegium Medicum Uniwersytetu Jagiellońskiego, Kraków, Polska, Kierownik jednostki: dr hab. n. med. Mirosław Bik-Multanowski
  3. Zespół Opieki Zdrowotnej, Kierownik jednostki: dr n. med. Ryszard Ściborski, Oława, Polska
  4. Klinika Pediatrii, Endokrynologii, Diabetologii, Chorób Metabolicznych i Kardiologii Wieku Rozwojowego, Pomorski Uniwersytet Medyczny, Kierownik jednostki: prof. dr hab. n. med. Mieczysław Walczak, Szczecin, Polska
  5. Oddział Chorób Wewnętrznych Miedziowego Centrum Zdrowia S.A. w Lubinie, Kierownik jednostki: lek. Zbigniew Szpich, Lubin, Polska
  6. Proper Medical Writing, Warszawa, Polska
  7. Sanofi-Aventis sp. z o.o., Sanofi Genzyme, Warszawa, Polska
  8. Wydział Medyczny, Uniwersytet Rzeszowski, Rzeszów, Polska
  9. Hematology Center Karolinska, Karolinska University Hospital Huddinge, Sztokholm, Szwecja

open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2017-10-15

Abstract

The following recommendations are the first complete document concerning the diagnosis, treatment and monitoring of Gaucher disease (GD) in Poland. GD is a rare, genetically determined storage disorder, involving deficiency or absence of glucocerebrosidase activity, a lysosomal enzyme that digests glucosylceramide. Glucosylceramide excessively accumulates in the monocyte-macrophage system (Gaucher cells), which in turn accumulate primarily in the bone marrow, spleen and liver. In the most severe forms of the disease, central nervous system is also involved. There are three clinical types of Gaucher disease, and the primary criteria for their differentiation is the involvement of the central nervous system, and the rate of symptom progression. The least severe and most common is type 1 GD, characterised mainly by hematological manifestations, such as thrombocytopenia and anemia, splenomegaly, hepatomegaly and skeletal involvement (bone pain, bone deformities, pathological fractures). Types 2 and 3 GD involve various central nervous system manifestations. Diagnosis of Gaucher disease is difficult, particularly in individuals from families without prior GD history. Gaucher disease is characterised by a heterogenic disease course and is rarely considered in differential diagnosis. This presents a major problem, as correct diagnosis and treatment implementation are often delayed by many years. This can lead to serious complications and even premature death of the patient. Currently, the primary therapeutic approach is an enzyme replacement therapy, involving an intravenous administration of recombinant glucocerebrosidase. Treatment of mild and moderate forms of the disease also includes an oral therapy which inhibits the production of glucocerebroside.

Abstract

The following recommendations are the first complete document concerning the diagnosis, treatment and monitoring of Gaucher disease (GD) in Poland. GD is a rare, genetically determined storage disorder, involving deficiency or absence of glucocerebrosidase activity, a lysosomal enzyme that digests glucosylceramide. Glucosylceramide excessively accumulates in the monocyte-macrophage system (Gaucher cells), which in turn accumulate primarily in the bone marrow, spleen and liver. In the most severe forms of the disease, central nervous system is also involved. There are three clinical types of Gaucher disease, and the primary criteria for their differentiation is the involvement of the central nervous system, and the rate of symptom progression. The least severe and most common is type 1 GD, characterised mainly by hematological manifestations, such as thrombocytopenia and anemia, splenomegaly, hepatomegaly and skeletal involvement (bone pain, bone deformities, pathological fractures). Types 2 and 3 GD involve various central nervous system manifestations. Diagnosis of Gaucher disease is difficult, particularly in individuals from families without prior GD history. Gaucher disease is characterised by a heterogenic disease course and is rarely considered in differential diagnosis. This presents a major problem, as correct diagnosis and treatment implementation are often delayed by many years. This can lead to serious complications and even premature death of the patient. Currently, the primary therapeutic approach is an enzyme replacement therapy, involving an intravenous administration of recombinant glucocerebrosidase. Treatment of mild and moderate forms of the disease also includes an oral therapy which inhibits the production of glucocerebroside.

Get Citation

Keywords

Gaucher disease; Clinical symptoms; Children; Adults; Treatment; Monitoring

About this article
Title

Gaucher disease – recommendations concerning diagnosis, treatment and monitoring

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 4 (2017)

Pages

222-261

Published online

2017-10-01

DOI

10.1016/j.achaem.2017.10.001

Bibliographic record

Acta Haematol Pol 2017;48(4):222-261.

Keywords

Gaucher disease
Clinical symptoms
Children
Adults
Treatment
Monitoring

Authors

Piotr Hasiński
Mirosław Bik-Multanowski
Magdalena Koba-Wszędobył
Mieczysław Walczak
Marek Bubnowski
Agnieszka Milewska-Kranc
Andrzej Smyk
Maciej Machaczka

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl